

DAFTAR PUSTAKA

- Aapro, M. (2018). CINV: still troubling patients after all these years. *Supportive Care in Cancer*, 26. <https://doi.org/10.1007/s00520-018-4131-3>
- Arora, T., Mullangi, S., & Lekalla, M. (2021, September 9). *Ovarian Cancer*. StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK567760/>
- Budiana, I. N. G., Angelina, M., & Pemayun, T. G. A. (2019). Ovarian cancer: Pathogenesis and current recommendations for prophylactic surgery. *Journal of the Turkish-German Gynecological Association*, 20(1). <https://doi.org/10.4274/jtgga.galenos.2018.2018.0119>
- Cremasco, M. M., Mulasso, A., Moroni, A., Testa, A., Degan, R., Rainoldi, A., & Rabaglietti, E. (2021). Relation among perceived weight change, sedentary activities and sleep quality during covid-19 lockdown: A study in an academic community in Northern Italy. *International Journal of Environmental Research and Public Health*, 18(6). <https://doi.org/10.3390/ijerph18062943>
- Gilmore, J. W., Peacock, N. W., Gu, A., Szabo, S., Rammage, M., Sharpe, J., Haislip, S. T., Perry, T., Boozan, T. L., Meador, K., Cao, X., & Burke, T. A. (2014). Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE study. *Journal of Oncology Practice*, 10(1). <https://doi.org/10.1200/JOP.2012.000816>
- Gupta, K., Walton, R., & Kataria, S. P. (2021). Chemotherapy-Induced Nausea and Vomiting: Pathogenesis, Recommendations, and New Trends. In *Cancer Treatment and Research Communications* (Vol. 26). <https://doi.org/10.1016/j.ctarc.2020.100278>
- Hayashi, M., Nakazawa, K., Hasegawa, Y., Horiguchi, J., Miura, D., Ishikawa, T., Takao, S., Kim, S. J. I. M., Yamagami, K., Miyashita, M., Konishi, M., Shigeoka, Y., Suzuki, M., Taguchi, T., Kubota, T., Tanino, H., Yamada, K., Narui, K., Kimura, K., ... Kohno, N. (2019). Risk Analysis for Chemotherapy-induced Nausea and Vomiting (CINV) in Patients Receiving FEC100 Treatment. In *Anticancer Research* (Vol. 39, Issue 8). <https://doi.org/10.21873/anticanres.13596>

- Kawazoe, H., Murakami, A., Yamashita, M., Nishiyama, K., Kobayashi-Taguchi, K., Komatsu, S., Aoki, R., Kusakabe, E., Yamasawa, H., Yakushijin, Y., Nakamura, T., & Kamei, Y. (2018). Patient-related Risk Factors for Nausea and Vomiting with Standard Antiemetics in Patients with Breast Cancer Receiving Anthracycline-based Chemotherapy: A Retrospective Observational Study. *Clinical Therapeutics*, 40(12). <https://doi.org/10.1016/j.clinthera.2018.10.004>
- Matulonis, U. A., Sood, A. K., Fallowfield, L., Howitt, B. E., Sehouli, J., & Karlan, B. Y. (2016). Ovarian cancer. *Nature Reviews Disease Primers*, 2. <https://doi.org/10.1038/nrdp.2016.61>
- Mosa, A. S. M., Mosharraf Hossain, A., Lavoie, B. J., & Yoo, I. (2020). Patient-related risk factors for Chemotherapy-Induced Nausea and Vomiting: A systematic review. *Frontiers in Pharmacology*, 11. <https://doi.org/10.3389/fphar.2020.00329>
- Nishida, C., Barba, C., Cavalli-Sforza, T., Cutter, J., Deurenberg, P., Darnton-Hill, I., Deurenberg-Yap, M., Gill, T., James, P., Ko, G., Kosulwat, V., Kumanyika, S., Kurpad, A., Mascie-Taylor, N., Moon, H. K., Nakadomo, F., Nishida, C., Noor, M. I., Reddy, K. S., ... Zimmet, P. (2004). Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. *The Lancet*, 363(9403). [https://doi.org/10.1016/S0140-6736\(03\)15268-3](https://doi.org/10.1016/S0140-6736(03)15268-3)
- Ojima, I., Lichtenthal, B., Lee, S., Wang, C., & Wang, X. (2016). Taxane anticancer agents: A patent perspective. In *Expert Opinion on Therapeutic Patents* (Vol. 26, Issue 1). <https://doi.org/10.1517/13543776.2016.1111872>
- Oun, R., Moussa, Y. E., & Wheate, N. J. (2018). The side effects of platinum-based chemotherapy drugs: A review for chemists. In *Dalton Transactions* (Vol. 47, Issue 19). <https://doi.org/10.1039/c8dt00838h>
- Pentheroudakis, G., Razis, E., Athanassiadis, A., Pavlidis, N., & Fountzilas, G. (2006). Paclitaxel-carboplatin combination chemotherapy in advanced breast cancer: Accumulating evidence for synergy, efficacy, and safety. In *Medical Oncology* (Vol. 23, Issue 2). <https://doi.org/10.1385/MO:23:2:147>
- Prat, J., Belhadj, H., Berek, J., Bermudez, A., Bhatla, N., Cain, J., Denny, L., Fujiwara, K., Hacker, N., Åvall-Lundqvist, E., Mutch, D., Odicino, F., Pecorelli, S., Prat, J.,

- Quinn, M., Seoud, M. A. F., & Shrivastava, S. K. (2015). Figo's staging classification for cancer of the ovary, fallopian tube, and peritoneum: Abridged republication. *Journal of Gynecologic Oncology*, 26(2). <https://doi.org/10.3802/jgo.2015.26.2.87>
- Rao, K. v., & Faso, A. (2012). Chemotherapy-induced nausea and vomiting: Optimizing prevention and management. *American Health and Drug Benefits*, 5(4).
- Roila, F., & Fatigoni, S. (2006). New antiemetic drugs. In *Annals of Oncology* (Vol. 17, Issue SUPPL. 2). <https://doi.org/10.1093/annonc/mdj936>
- Sekine, I., Segawa, Y., Kubota, K., & Saeki, T. (2013). Risk factors of chemotherapy-induced nausea and vomiting: Index for personalized antiemetic prophylaxis. *Cancer Science*, 104(6). <https://doi.org/10.1111/cas.12146>
- Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2022). Cancer statistics, 2022. *CA: A Cancer Journal for Clinicians*, 72(1). <https://doi.org/10.3322/caac.21708>
- Smit, C., de Hoogd, S., Brüggemann, R. J. M., & Knibbe, C. A. J. (2018). Obesity and drug pharmacology: a review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters. In *Expert Opinion on Drug Metabolism and Toxicology* (Vol. 14, Issue 3). <https://doi.org/10.1080/17425255.2018.1440287>
- Verbraecken, J., van de Heyning, P., de Backer, W., & van Gaal, L. (2006). Body surface area in normal-weight, overweight, and obese adults. A comparison study. *Metabolism: Clinical and Experimental*, 55(4). <https://doi.org/10.1016/j.metabol.2005.11.004>
- World Health Organization. (2020). *Indonesia Cancer Country Profile*. https://www.who.int/cancer/country-profiles/IDN_2020.pdf